News & Posts

blog.1.image
Antibody industry insights

Therapeutic antibody licensing deals in China a 2022 end of year summary

We will continue to provide comprehensive analysis and reports about therapeutic antibody licensing deals between Chinese biopharma and overseas companies. In this third business report on this topic, we focus on licensing deals closed in 2022.

Posted on March 9, 2023
9 minutes read

Read Story
blog.5.image

FcRn-Targeted Therapies for Autoimmune Disorders Summit

The digital FcRn-Targeted Therapies for Autoimmune Disorders Summit will be virtually held from 23-25, March 2021

less than a minute read

Read Story
blog.5.image

CHI Meetings

10% off registration fee for CAS members when registering for 2021 CHI Meetings

less than a minute read

Read Story
blog.5.image

Antibody Engineering & Therapeutics (AET) Collaboration

The Chinese Antibody Society (CAS) and the organizing committee of the Antibody Engineering & Therapeutics (AET) conference have entered into a collaboration

1 minute read

Read Story
blog.5.image

Parternship with Cambridge Healthtech Institute

The Chinese Antibody Society and Cambridge Healthtech Institute Announce Strategic Partnership

2 minutes read

Read Story
This web app is a Python Django project independently coded (frontend+backend+deployment on AWS) by Xin Yu (Github, LinkedIn) in her volunteer capacity at the Chinese Antibody Society. Contents are maintained by CAS IT team. If you're interested in participating in the future development of this web app, please submit a volunteer application and request an interview with the IT team. We require a minimum of 2 years experience as a Django developer. © Chinese Antibody Society 2021. All Rights Reserved. Legal Disclaimer
Icon